| Published Application/Species/Sample/Dilution | Reference |
|---|
- flow cytometry; human; loading ...; fig 1f
| Liu C, Zheng S, Wang Z, Wang S, Wang X, Yang L, et al. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. Cancer Commun (Lond). 2022;42:828-847 pubmed publisher |
- flow cytometry; human; loading ...; fig 6e
| Pinkert J, Boehm H, Trautwein M, Doecke W, Wessel F, Ge Y, et al. T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interaction. Oncoimmunology. 2022;11:2008110 pubmed publisher |
- flow cytometry; mouse; 1:200; loading ...; fig s1a
| Luo N, Formisano L, Gonzalez Ericsson P, Sanchez V, Dean P, Opalenik S, et al. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. Oncoimmunology. 2018;7:e1438106 pubmed publisher |
- flow cytometry; human; loading ...; fig s1
| Ashizawa T, Iizuka A, Nonomura C, Kondou R, Maeda C, Miyata H, et al. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse. Clin Cancer Res. 2017;23:149-158 pubmed publisher |
- flow cytometry; human; 1:200; fig 2
| Johnson D, Estrada M, Salgado R, Sanchez V, Doxie D, Opalenik S, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7:10582 pubmed publisher |
- immunohistochemistry; human; 1:100
| Miranda A, Funes J, Sánchez N, Limia C, Mesa M, Quezada S, et al. Oncogenic Transformation Can Orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure. Cancer Res. 2015;75:3032-42 pubmed publisher |
- flow cytometry; human; fig 6
| Rancan C, Schirrmann L, Hüls C, Zeidler R, Moosmann A. Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells. PLoS Pathog. 2015;11:e1004906 pubmed publisher |
| Izmirly A, Pelletier A, Connors J, Taramangalam B, Alturki S, Gordon E, et al. Pre-vaccination frequency of circulatory Tfh is associated with robust immune response to TV003 dengue vaccine. PLoS Pathog. 2022;18:e1009903 pubmed publisher |
| Fu H, Lu J, Zhang X, Wang B, Sun Y, Lei Y, et al. Identification of the Recombinant Plasmodium vivax Surface-Related Antigen as a Possible Immune Evasion Factor Against Human Splenic Fibroblasts by Targeting ITGB1. Front Cell Dev Biol. 2021;9:764109 pubmed publisher |
| Chen L, Chai J, Liu B, Strutt T, McKinstry K, Chai K. Prostasin regulates PD-L1 expression in human lung cancer cells. Biosci Rep. 2021;41: pubmed publisher |
| Chen L, Chai J, Liu B, Strutt T, McKinstry K, Chai K. Prostasin regulates PD-L1 expression in human lung cancer cells. Biosci Rep. 2021;: pubmed publisher |
| O Connor M, Muir R, Chakhtoura M, Fang M, Moysi E, Moir S, et al. A follicular regulatory Innate Lymphoid Cell population impairs interactions between germinal center Tfh and B cells. Commun Biol. 2021;4:563 pubmed publisher |
| Ng W, Gong C, Yan X, Si G, Fang C, Wang L, et al. Targeting CD155 by rediocide-A overcomes tumour immuno-resistance to natural killer cells. Pharm Biol. 2021;59:47-53 pubmed publisher |
| Sam J, Colombetti S, Fauti T, Roller A, Biehl M, Fahrni L, et al. Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity. Front Oncol. 2020;10:575737 pubmed publisher |
| Zhang Y, Dong X, Bai L, Shang X, Zeng Y. MUC1-induced immunosuppression in colon cancer can be reversed by blocking the PD1/PDL1 signaling pathway. Oncol Lett. 2020;20:317 pubmed publisher |
| Huang B, Liu Y, Lai S, Lin H, Shen C, Yang L, et al. CAIX Regulates GBM Motility and TAM Adhesion and Polarization through EGFR/STAT3 under Hypoxic Conditions. Int J Mol Sci. 2020;21: pubmed publisher |
| Leite N, Sintov E, Meissner T, Brehm M, Greiner D, Harlan D, et al. Modeling Type 1 Diabetes In Vitro Using Human Pluripotent Stem Cells. Cell Rep. 2020;32:107894 pubmed publisher |
| Lim K, Han Z, Jeon H, Kach J, Jing E, Weyn Vanhentenryck S, et al. Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression. Nat Commun. 2020;11:3501 pubmed publisher |
| Fu Y, Liu C, Kobayashi D, Johanns T, Bowman Kirigin J, Schaettler M, et al. GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors. Sci Rep. 2020;10:9027 pubmed publisher |
| Sun X, Li C, Wang W, Chen M, Li H, Lai Y, et al. Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma. Am J Cancer Res. 2020;10:564-571 pubmed |
| Cui J, Wang H, Medina R, Zhang Q, Xu C, Indig I, et al. Inhibition of PP2A with LB-100 Enhances Efficacy of CAR-T Cell Therapy Against Glioblastoma. Cancers (Basel). 2020;12: pubmed publisher |
| Renner K, Bruss C, Schnell A, Koehl G, Becker H, Fante M, et al. Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy. Cell Rep. 2019;29:135-150.e9 pubmed publisher |
| Rauch D, Conlon K, Janakiram M, Brammer J, Harding J, Ye B, et al. Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade. Blood. 2019;134:1406-1414 pubmed publisher |
| Ofori S, Awuah S. Small-Molecule Poly(ADP-ribose) Polymerase and PD-L1 Inhibitor Conjugates as Dual-Action Anticancer Agents. ACS Omega. 2019;4:12584-12597 pubmed publisher |
| Wallstabe L, Göttlich C, Nelke L, Kühnemundt J, Schwarz T, Nerreter T, et al. ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI Insight. 2019;4: pubmed publisher |
| Palakurthi S, Kuraguchi M, Zacharek S, Zudaire E, Huang W, Bonal D, et al. The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity. Cancer Immunol Res. 2019;7:1457-1471 pubmed publisher |
| Chan L, Li C, Xia W, Hsu J, Lee H, Cha J, et al. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 2019;129:3324-3338 pubmed publisher |
| Jin M, Nam A, Park J, Bang J, Bang Y, Oh D. Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer. Cancer Res Treat. 2020;52:149-166 pubmed publisher |
| Jiang L, Guo F, Liu X, Li X, Qin Q, Shu P, et al. Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC. Sci Rep. 2019;9:3705 pubmed publisher |
| Kuryk L, Møller A, Jaderberg M. Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model. Oncoimmunology. 2019;8:e1532763 pubmed publisher |
| Hassounah N, Malladi V, Huang Y, Freeman S, Beauchamp E, Koyama S, et al. Identification and characterization of an alternative cancer-derived PD-L1 splice variant. Cancer Immunol Immunother. 2019;68:407-420 pubmed publisher |
| Saraiva D, Jacinto A, Borralho P, Braga S, Cabral M. HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy. Front Immunol. 2018;9:2605 pubmed publisher |
| Su S, Zhao J, Xing Y, Zhang X, Liu J, Ouyang Q, et al. Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages. Cell. 2018;175:442-457.e23 pubmed publisher |
| Koopmans I, Hendriks D, Samplonius D, van Ginkel R, Heskamp S, Wierstra P, et al. A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint. Oncoimmunology. 2018;7:e1466016 pubmed publisher |
| Zhao L, Niu C, Shi X, Xu D, Li M, Cui J, et al. Dendritic cells loaded with the lysate of tumor cells infected with Newcastle Disease Virus trigger potent anti-tumor immunity by promoting the secretion of IFN-γ and IL-2 from T cells. Oncol Lett. 2018;16:1180-1188 pubmed publisher |
| Capuano C, Battella S, Pighi C, Franchitti L, Turriziani O, Morrone S, et al. Tumor-Targeting Anti-CD20 Antibodies Mediate In Vitro Expansion of Memory Natural Killer Cells: Impact of CD16 Affinity Ligation Conditions and In Vivo Priming. Front Immunol. 2018;9:1031 pubmed publisher |
| Wang B, Zuo J, Kang W, Wei Q, Li J, Wang C, et al. Generation of Hutat2:Fc Knockin Primary Human Monocytes Using CRISPR/Cas9. Mol Ther Nucleic Acids. 2018;11:130-141 pubmed publisher |
| Yang W, Cha J, Xia W, Lee H, Chan L, Wang Y, et al. Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression. Cancer Res. 2018;78:3761-3768 pubmed publisher |
| Hsu J, Xia W, Hsu Y, Chan L, Yu W, Cha J, et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun. 2018;9:1908 pubmed publisher |
| Gorris M, Halilovic A, Rabold K, van Duffelen A, Wickramasinghe I, Verweij D, et al. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment. J Immunol. 2018;200:347-354 pubmed publisher |
| Saha D, Martuza R, Rabkin S. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. Cancer Cell. 2017;32:253-267.e5 pubmed publisher |
| Jiao S, Xia W, Yamaguchi H, Wei Y, Chen M, Hsu J, et al. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017;23:3711-3720 pubmed publisher |
| Mackroth M, Abel A, Steeg C, Schulze zur Wiesch J, Jacobs T. Acute Malaria Induces PD1+CTLA4+ Effector T Cells with Cell-Extrinsic Suppressor Function. PLoS Pathog. 2016;12:e1005909 pubmed publisher |
| An L, Gorman J, Stephens G, Swerdlow B, Warrener P, Bonnell J, et al. Complement C5a induces PD-L1 expression and acts in synergy with LPS through Erk1/2 and JNK signaling pathways. Sci Rep. 2016;6:33346 pubmed publisher |
| Hsu H, Boudová S, Mvula G, Divala T, Mungwira R, Harman C, et al. Prolonged PD1 Expression on Neonatal V?2 Lymphocytes Dampens Proinflammatory Responses: Role of Epigenetic Regulation. J Immunol. 2016;197:1884-92 pubmed publisher |
| Maute R, Gordon S, Mayer A, McCracken M, Natarajan A, Ring N, et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci U S A. 2015;112:E6506-14 pubmed publisher |
| Boyerinas B, Jochems C, Fantini M, Heery C, Gulley J, Tsang K, et al. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015;3:1148-1157 pubmed publisher |
| Atefi M, Avramis E, Lassen A, Wong D, Robert L, Foulad D, et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res. 2014;20:3446-57 pubmed publisher |
| Jiang X, Zhou J, Giobbie Hurder A, Wargo J, Hodi F. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res. 2013;19:598-609 pubmed publisher |
